New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

MannKind Corporation (MNKD) vs Ocular Therapeutix, Inc. (OCUL)

MannKind Corporation and Ocular Therapeutix, Inc. are both Biotechnology companies. MannKind Corporation and Ocular Therapeutix, Inc. are of similar size ($1.4B and $1.3B). MannKind Corporation grew revenue faster over the last twelve months: 31.7% against −9.68%. MannKind Corporation has the higher net margin (−18.1% vs −648.6%) and the lower return on invested capital (−2.58% vs 0.00%). Across the 17 metrics below, MannKind Corporation leads on 12 and Ocular Therapeutix, Inc. on 5.

Valuation

Metric MNKD OCUL Biotechnology median
P/E n/m n/m 8.26
P/S 3.05 26.23 9.20
P/B n/m 3.00 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 102.26 n/m 0.67
EV/Sales 3.84 17.16 9.05
Earnings yield (5.84%) (24.92%) (34.24%)
Free cash flow yield (6.22%) (20.21%) (24.77%)

Profitability

Metric MNKD OCUL Biotechnology median
Gross margin 75.76% 87.32% 70.18%
Operating margin (2.88%) (680.91%) 0.00%
Net margin (18.10%) (648.64%) 0.00%
Free cash flow margin (18.97%) (530.00%) 0.00%
Return on equity 182.90% (93.48%) (51.58%)
Return on assets (12.29%) (64.30%) (45.91%)
Return on invested capital (2.58%) 0.00% 0.00%

Growth

Metric MNKD OCUL Biotechnology median
Revenue growth (TTM) 31.74% (9.68%) 7.20%
EPS growth (last fiscal year) (80.00%) (16.39%) 29.04%
Revenue growth, 5-year CAGR 39.89% 24.45% 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNKD OCUL Biotechnology median
Debt to equity (11.33) 0.17 0.00
Current ratio 2.22 9.12 4.83
Net debt to EBITDA 5.32 2.51 1.01

Dividend

Metric MNKD OCUL Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric MNKD OCUL Biotechnology median
Market cap 1.35b 1.29b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack